Paris, March 20th 2017 – Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventor of Cellvizio®, the...
Mauna Kea Technologies confirms its eligibility to the French PEA-PME investment vehicles for 2017/2018
read more
Search Results
Mauna Kea appoints Jennifer F. Tseng, M.D. to Board of Directors
Leading Surgical Oncologist and GI Specialist to Add Clinical Expertise Paris, France and Cambridge, MA, USA, March 13, 2017 - Mauna Kea...
Superiority of Endomicroscopy for the Diagnosis of Gastric Cancer Highlighted in a Peer-Reviewed Publication Comparing Advanced Imaging Technologies
Meta-Analysis Shows Superiority Compared to Other Imaging Modalities Paris, March 2, 2017 – Mauna Kea Technologies (Euronext: MKEA, OTCQX:...
Mauna Kea Technologies Secures a €7.0 million Debt Financing
Paris, February 8, 2017 – Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal...
Mauna Kea Technologies Appoints John Soto As Chief Operating Officer
Addition of Seasoned Medical Device Executive with Decades of Experience in U.S. and Global Markets Strengthens Global Leadership Team Paris,...
Mauna Kea Technologies reports fourth quarter and full year 2016 sales
Click to read more
Half-yearly report on the liquidity contract with Gilbert Dupont
Paris, France, January 2, 2017 Pursuant to the liquidity contract entrusted to Gilbert Dupont, on 31 December 2016 the following assets appeared on...
PERSEE Study demonstrates applicability of Cellvizio in surgical interventions for digestive cancers, triggering milestone payment from BpiFrance
Results from PERSEE Study Published in Surgical Endoscopy and European Journal of Gastroenterology & Hepatology Mauna Kea Technologies receives...
Mauna Kea Technologies secures an Equity Financing Facility
Click to read more
Mauna Kea Technologies Reports third quarter 2016 Sales
Click to read more
Reimbursement increases of 131% for hospitals and 86% for ambulatory surgical centers for key Cellvizio procedures
Click to read more
Cellvizio®’s strong clinical efficacy in the prevention of certain pancreatic cancers confirmed by positive results from CONTACT study presented at UEGW 2016
Click to read more